Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein. Cell junction Cell junction, focal adhesion Cytoplasm, cytoskeleton. Secreted Note=Recruited to cell-cell contacts in quiescent endothelial cells (PubMed:18425120, PubMed:18425119). Colocalizes with the actin cytoskeleton and at actin stress fibers during cell spreading. Recruited to the lower surface of migrating cells, especially the rear end of the cell. Proteolytic processing gives rise to a soluble extracellular domain that is secreted (PubMed:11806244). |
Domain |
PF00041 Fibronectin type III domain PF10430 Tie-2 Ig-like domain 1 PF07714 Protein tyrosine kinase |
Function |
Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1. |
Biological Process |
GO:0001501 skeletal system development GO:0001503 ossification GO:0001525 angiogenesis GO:0001666 response to hypoxia GO:0001667 ameboidal-type cell migration GO:0001935 endothelial cell proliferation GO:0001936 regulation of endothelial cell proliferation GO:0001938 positive regulation of endothelial cell proliferation GO:0001952 regulation of cell-matrix adhesion GO:0001954 positive regulation of cell-matrix adhesion GO:0001958 endochondral ossification GO:0002040 sprouting angiogenesis GO:0003007 heart morphogenesis GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0003205 cardiac chamber development GO:0003206 cardiac chamber morphogenesis GO:0006644 phospholipid metabolic process GO:0007044 cell-substrate junction assembly GO:0007045 cell-substrate adherens junction assembly GO:0007160 cell-matrix adhesion GO:0007163 establishment or maintenance of cell polarity GO:0007507 heart development GO:0008015 blood circulation GO:0010594 regulation of endothelial cell migration GO:0010595 positive regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010634 positive regulation of epithelial cell migration GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014074 response to purine-containing compound GO:0016525 negative regulation of angiogenesis GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019216 regulation of lipid metabolic process GO:0030335 positive regulation of cell migration GO:0031348 negative regulation of defense response GO:0031532 actin cytoskeleton reorganization GO:0031589 cell-substrate adhesion GO:0032102 negative regulation of response to external stimulus GO:0032878 regulation of establishment or maintenance of cell polarity GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0033674 positive regulation of kinase activity GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0034332 adherens junction organization GO:0034333 adherens junction assembly GO:0034446 substrate adhesion-dependent cell spreading GO:0036075 replacement ossification GO:0036293 response to decreased oxygen levels GO:0040017 positive regulation of locomotion GO:0043114 regulation of vascular permeability GO:0043410 positive regulation of MAPK cascade GO:0043434 response to peptide hormone GO:0043491 protein kinase B signaling GO:0043542 endothelial cell migration GO:0043550 regulation of lipid kinase activity GO:0043551 regulation of phosphatidylinositol 3-kinase activity GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity GO:0043627 response to estrogen GO:0044089 positive regulation of cellular component biogenesis GO:0045216 cell-cell junction organization GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045785 positive regulation of cell adhesion GO:0045834 positive regulation of lipid metabolic process GO:0046683 response to organophosphorus GO:0046777 protein autophosphorylation GO:0048014 Tie signaling pathway GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048041 focal adhesion assembly GO:0048514 blood vessel morphogenesis GO:0048705 skeletal system morphogenesis GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050900 leukocyte migration GO:0051259 protein oligomerization GO:0051272 positive regulation of cellular component movement GO:0051493 regulation of cytoskeleton organization GO:0051495 positive regulation of cytoskeleton organization GO:0051591 response to cAMP GO:0051893 regulation of focal adhesion assembly GO:0051894 positive regulation of focal adhesion assembly GO:0051896 regulation of protein kinase B signaling GO:0051897 positive regulation of protein kinase B signaling GO:0060216 definitive hemopoiesis GO:0060343 trabecula formation GO:0060347 heart trabecula formation GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060350 endochondral bone morphogenesis GO:0061383 trabecula morphogenesis GO:0061384 heart trabecula morphogenesis GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070482 response to oxygen levels GO:0072577 endothelial cell apoptotic process GO:0090109 regulation of cell-substrate junction assembly GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090218 positive regulation of lipid kinase activity GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1901652 response to peptide GO:1901888 regulation of cell junction assembly GO:1901890 positive regulation of cell junction assembly GO:1903391 regulation of adherens junction organization GO:1903393 positive regulation of adherens junction organization GO:1903725 regulation of phospholipid metabolic process GO:1903727 positive regulation of phospholipid metabolic process GO:1904018 positive regulation of vasculature development GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904036 negative regulation of epithelial cell apoptotic process GO:2000147 positive regulation of cell motility GO:2000181 negative regulation of blood vessel morphogenesis GO:2000249 regulation of actin cytoskeleton reorganization GO:2000251 positive regulation of actin cytoskeleton reorganization GO:2000351 regulation of endothelial cell apoptotic process GO:2000352 negative regulation of endothelial cell apoptotic process |
Molecular Function |
GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0019199 transmembrane receptor protein kinase activity GO:0019838 growth factor binding |
Cellular Component |
GO:0001725 stress fiber GO:0005884 actin filament GO:0005902 microvillus GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009925 basal plasma membrane GO:0015629 actin cytoskeleton GO:0016323 basolateral plasma membrane GO:0016324 apical plasma membrane GO:0030055 cell-substrate junction GO:0032432 actin filament bundle GO:0042641 actomyosin GO:0045121 membrane raft GO:0045177 apical part of cell GO:0045178 basal part of cell GO:0097517 contractile actin filament bundle GO:0098589 membrane region GO:0098857 membrane microdomain GO:0098858 actin-based cell projection |
KEGG |
hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04066 HIF-1 signaling pathway hsa04151 PI3K-Akt signaling pathway |
Reactome |
R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-210993: Tie2 Signaling R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TEK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between TEK and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TEK in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TEK in various data sets.
|
Points in the above scatter plot represent the mutation difference of TEK in various data sets.
|
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TEK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TEK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TEK. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TEK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TEK expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TEK and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | TEK |
Name | TEK tyrosine kinase, endothelial |
Aliases | TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ...... |
Chromosomal Location | 9p21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting TEK collected from DrugBank database. |
Details on drugs targeting TEK.
|